{"url_path":"/sec/cik-0001657677/8-k/2026-06-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1657677/0001193125-26-267550-index.html","accession_number":"0001193125-26-267550","cik":"0001657677","ticker":null,"issuer_name":"Parabilis Medicines, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1657677/0001193125-26-267550-index.html","primary_entity_key":"0001657677","primary_entity_name":"Parabilis Medicines, Inc."},"word_count":103,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\n 3.1\n\n[Seventh Amended and Restated Certificate of Incorporation of Parabilis Medicines, Inc.](ck0001657677-ex3_1.htm)\n\n \n\n \n\n 3.2\n\n[Amended and Restated Bylaws of Parabilis Medicines, Inc.](ck0001657677-ex3_2.htm)\n\n \n\n \n\n \n\n10.1\n\n \n\n[Stock Purchase Agreement, by and between the Company and Regeneron Pharmaceuticals, Inc.](ck0001657677-ex10_1.htm)\n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\nParabilis Medicines, Inc.\n\n \n\n \n\n \n\nDate: June 11, 2026\n\nBy:\n\n/s/ Thomas Kotarakos\n\n \n\n \n\nThomas Kotarakos\n\n \n\n \n\nChief Financial Officer"}